AR059571A1 - Derivados de octahidro-pirrolo[3,4-c]pirrol, composiciones farmaceuticas - Google Patents
Derivados de octahidro-pirrolo[3,4-c]pirrol, composiciones farmaceuticasInfo
- Publication number
- AR059571A1 AR059571A1 ARP070100591A ARP070100591A AR059571A1 AR 059571 A1 AR059571 A1 AR 059571A1 AR P070100591 A ARP070100591 A AR P070100591A AR P070100591 A ARP070100591 A AR P070100591A AR 059571 A1 AR059571 A1 AR 059571A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- formula
- hydrogen
- group
- rest
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 9
- 239000001257 hydrogen Substances 0.000 abstract 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 7
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 4
- -1 cyano, hydroxyl Chemical group 0.000 abstract 4
- 150000002431 hydrogen Chemical group 0.000 abstract 4
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical group C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 abstract 2
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 abstract 1
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 abstract 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 abstract 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 abstract 1
- 102000004274 CCR5 Receptors Human genes 0.000 abstract 1
- 108010017088 CCR5 Receptors Proteins 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 101100134929 Gallus gallus COR9 gene Chemical group 0.000 abstract 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 1
- 101150020251 NR13 gene Proteins 0.000 abstract 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Chemical group C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 abstract 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000003566 oxetanyl group Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Chemical group O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 abstract 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 abstract 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente proporciona además métodos para tratar enfermedades que se alivian con antagonistas de CCR5. La presente incluye composiciones farmacéuticas y métodos para el uso de los compuestos destinados a tratar enfermedades mediadas por el receptor CCR5, particularmente para tratar o prevenir una infeccion por virus VIH-1. Reivindicacion 1: Un compuesto de la formula (1) en la que: uno de R1 y R2 es fenilo opcionalmente sustituido de una a cuatro veces por sustituyentes elegidos con independencia entre sí entre el grupo formado por halogeno, alquilo C1-6 y alcoxi C1-6; y los demás de R1 y R2 son hidrogeno; R3 se elige entre el grupo formado por: (a)cicloalquilo C3-7 opcionalmente sustituido de 1 a 4 veces por fluor, ciano, hidroxilo, alquilo C1-3 o fenilo, 4-oxo-ciclohexilo o 3-oxo-ciclobutilo; (b) heterociclo elegido de entre el grupo de formulas (2), oxetanilo y tetrahidrofuranilo, en los que: R8 es hidrogeno, COR9, COCHR14NHR15 o SO2R10; y R9 es alquilo C1-6 o cicloalquilo C3-7; R10 es alquilo C1-6; R14 es la cadena lateral de un aminoácido de origen natural; R15 es hidrogeno, tert-butoxicarbonilo o benciloxicarbonilo; (c) alquilo C1-6; y (d) alcoxi C1-6; R6 es hidrogeno, alquilo C1-3, haloalquilo C1-3, hidroxialquilo C1-6 u oxo-alquilo C1-3; R6a, R6b, R6c y R6d con independencia entre sí son hidrogeno o alquilo C1-3, con la condicion de que por lo menos uno de R6c sea hidrogeno; X1 se elige entre el grupo formado por (i)-(ix) y (x) en los que: X2 es N o CH; X2a es N, CH o CCl; A1 es fenileno o alquileno C1-6 de cadena lineal o ramificada, que está opcionalmente sustituido por un anillo fenilo; R5 es hidroxi, alcoxi C1-6, benciloxi o NR6aR6b; (i) el resto de formula (3), en la que R4 es C(=O)R5 o hidrogeno; (ii) el resto de formula (4), con la condicion de que A1 sea distinto de fenileno; (iii) el resto de formula (5); (iv) un resto de formula (6); (v) el resto de formula (7); (vi) un resto de formula (8), en los que: R7 es cicloalquilo C3-7, (CH2)nCOR5, heteroarilo elegido entre el grupo formado por piridina, pirimidina, pirazina y piridazina, dicho heteroarilo está opcionalmente sustituido por alquilo C1-3 o haloalquilo C1-3; n es un numero de 1 a 3; (vii) el resto de formula (9); (viii) el resto de formula (10), en la que X3 es -S(O)2- o -C(O)-; (ix) el resto de formula (11); (x) el resto de formula (12), en la que: R11 y R12 son (A) juntos un grupo (CH2)2X4(CH2)2, (CH2)2CH-(R16)CH2, (CH2)2SO2, o (B) con independencia R12 es hidrogeno o alquilo C1-3 y R11 es -SO2-alquilo C1-6, hidroxialquilo C1-6 o un resto seleccionado del grupo de formulas (15); X4 es O, S(O)m, NR13 o CH(NHSO2-alquilo C1-6); R13 es R6d, -C(O)-alquilo C1-6, S(O)2-alquilo C1-6; R16 es hidrogeno, hidroxilo o aciloxi C1-6; m es un numero de 0 a 2; (xi) el resto de formula (13) en la que R6e es hidroxialquilo C1-6 u oxo-alquilo C1-6; y (xii) el resto de formula (14) en la que R17 es cicloalquilo C3-5 o alquinilo C1-3; o sus sales, hidratos o solvatos farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77394206P | 2006-02-15 | 2006-02-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR059571A1 true AR059571A1 (es) | 2008-04-16 |
Family
ID=38157829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070100591A AR059571A1 (es) | 2006-02-15 | 2007-02-13 | Derivados de octahidro-pirrolo[3,4-c]pirrol, composiciones farmaceuticas |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20070191335A1 (es) |
| EP (1) | EP1987036A1 (es) |
| JP (1) | JP2009526803A (es) |
| KR (1) | KR20080102387A (es) |
| CN (1) | CN101384596A (es) |
| AR (1) | AR059571A1 (es) |
| AU (1) | AU2007216543A1 (es) |
| BR (1) | BRPI0710474A2 (es) |
| CA (1) | CA2641389A1 (es) |
| CL (1) | CL2007000362A1 (es) |
| IL (1) | IL193107A0 (es) |
| NO (1) | NO20083585L (es) |
| RU (1) | RU2008136756A (es) |
| TW (1) | TW200801010A (es) |
| WO (1) | WO2007093520A1 (es) |
| ZA (1) | ZA200806756B (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2641382A1 (en) * | 2006-02-15 | 2007-08-23 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| ATE472549T1 (de) | 2006-09-18 | 2010-07-15 | Hoffmann La Roche | Octahydropyrroloä3,4-cüpyrrolderivate und ihre verwendung als antivirale mittel |
| EP2099454A4 (en) * | 2006-11-17 | 2010-11-10 | Abbott Lab | AMINOPYRROLIDINES AS CHEMOKINE RECEPTOR ANTAGONISTS |
| US8464207B2 (en) * | 2007-10-12 | 2013-06-11 | Novell Intellectual Property Holdings, Inc. | System and method for tracking software changes |
| DE102010025663A1 (de) * | 2010-06-30 | 2012-01-05 | Karl-Heinz Glüsenkamp | Neue beta-Aminoaldehyd-Derivate, Verfahren zu ihrer Herstellung und ihre chemische Verwendung als reaktive Intermediate |
| US20140323306A1 (en) | 2011-11-14 | 2014-10-30 | Basf Se | Substituted 1,2,5-Oxadiazole Compounds and Their Use as Herbicides |
| JP2015519314A (ja) | 2012-04-27 | 2015-07-09 | ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ | 置換型ｎ−（テトラゾール−５−イル）−およびｎ−（トリアゾール−５−イル）ピリジン−３−イル−カルボキサミド化合物ならびに除草剤としてのそれらの使用 |
| EA027847B1 (ru) | 2012-04-27 | 2017-09-29 | Басф Се | Замещенные n-(тетразол-5-ил)- и n-(триазол-5-ил)арилкарбоксамидные соединения и их применение в качестве гербицидов |
| CN102718695B (zh) * | 2012-06-25 | 2014-04-02 | 华东师范大学 | 一种氮杂双环[3.3.0]辛烷衍生物的合成方法 |
| AR092211A1 (es) | 2012-09-24 | 2015-04-08 | Merck Patent Ges Mit Beschränkter Haftung | Derivados de hidropirrolopirrol |
| WO2014184058A1 (en) | 2013-05-15 | 2014-11-20 | Basf Se | Substituted 1,2,5-oxadiazole compounds and their use as herbicides |
| CN105209441A (zh) | 2013-05-15 | 2015-12-30 | 巴斯夫欧洲公司 | 取代的n-(四唑-5-基)-和n-(三唑-5-基)芳基羧酰胺化合物及其作为除草剂的用途 |
| EP3022190B1 (en) | 2013-07-18 | 2017-06-28 | Basf Se | N-(1,2,4-triazol-3-yl)-pyridin-2-yl-carboxamide derivatives as herbicides |
| US9902704B2 (en) | 2013-10-10 | 2018-02-27 | Basf Se | Substituted N-(tetrazol-5-yl)- and N-(triazol-5-yl)arylcarboxamide compounds and their use as herbicides |
| WO2015052178A1 (en) | 2013-10-10 | 2015-04-16 | Basf Se | 1,2,5-oxadiazole compounds and their use as herbicides |
| WO2015052173A1 (en) | 2013-10-10 | 2015-04-16 | Basf Se | Tetrazole and triazole compounds and their use as herbicides |
| EP2907807A1 (en) | 2014-02-18 | 2015-08-19 | Basf Se | Benzamide compounds and their use as herbicides |
| KR20180095901A (ko) | 2015-12-17 | 2018-08-28 | 바스프 에스이 | 벤즈아미드 화합물 및 제초제로서 그들의 용도 |
| KR20190026902A (ko) | 2016-07-14 | 2019-03-13 | 화이자 인코포레이티드 | 바닌-1 효소의 억제제로서의 신규 피리미딘 카르복스아미드 |
| AU2018275617A1 (en) | 2017-05-30 | 2019-12-19 | Basf Se | Benzamide compounds and their use as herbicides |
| US20210179569A1 (en) | 2017-05-30 | 2021-06-17 | Basf Se | Benzamide compounds and their use as herbicides ii |
| AR112112A1 (es) | 2017-06-20 | 2019-09-18 | Basf Se | Compuestos de benzamida y su uso como herbicidas |
| AR112342A1 (es) | 2017-07-21 | 2019-10-16 | Basf Se | Compuestos de benzamida y su uso como herbicidas |
| WO2019122345A1 (en) | 2017-12-22 | 2019-06-27 | Basf Se | Benzamide compounds and their use as herbicides |
| WO2019162308A1 (en) | 2018-02-21 | 2019-08-29 | Basf Se | Benzamide compounds and their use as herbicides |
| WO2019162309A1 (en) | 2018-02-21 | 2019-08-29 | Basf Se | Benzamide compounds and their use as herbicides |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2297727T3 (es) * | 2004-06-09 | 2008-05-01 | F. Hoffmann-La Roche Ag | Derivados de octahidropirrolo(3,4-c)pirrol y su empleo como agentes antiviricos. |
-
2007
- 2007-02-06 JP JP2008554728A patent/JP2009526803A/ja active Pending
- 2007-02-06 AU AU2007216543A patent/AU2007216543A1/en not_active Abandoned
- 2007-02-06 CA CA002641389A patent/CA2641389A1/en not_active Abandoned
- 2007-02-06 RU RU2008136756/04A patent/RU2008136756A/ru not_active Application Discontinuation
- 2007-02-06 KR KR1020087022382A patent/KR20080102387A/ko not_active Withdrawn
- 2007-02-06 WO PCT/EP2007/051099 patent/WO2007093520A1/en not_active Ceased
- 2007-02-06 CN CNA2007800051374A patent/CN101384596A/zh active Pending
- 2007-02-06 EP EP07704382A patent/EP1987036A1/en not_active Withdrawn
- 2007-02-06 BR BRPI0710474-0A patent/BRPI0710474A2/pt not_active IP Right Cessation
- 2007-02-12 TW TW096105067A patent/TW200801010A/zh unknown
- 2007-02-12 CL CL2007000362A patent/CL2007000362A1/es unknown
- 2007-02-13 AR ARP070100591A patent/AR059571A1/es unknown
- 2007-02-15 US US11/706,807 patent/US20070191335A1/en not_active Abandoned
-
2008
- 2008-07-29 IL IL193107A patent/IL193107A0/en unknown
- 2008-08-05 ZA ZA200806756A patent/ZA200806756B/xx unknown
- 2008-08-19 NO NO20083585A patent/NO20083585L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2008136756A (ru) | 2010-03-20 |
| CL2007000362A1 (es) | 2008-01-11 |
| IL193107A0 (en) | 2009-02-11 |
| CN101384596A (zh) | 2009-03-11 |
| EP1987036A1 (en) | 2008-11-05 |
| US20070191335A1 (en) | 2007-08-16 |
| KR20080102387A (ko) | 2008-11-25 |
| CA2641389A1 (en) | 2007-08-23 |
| JP2009526803A (ja) | 2009-07-23 |
| BRPI0710474A2 (pt) | 2011-08-16 |
| ZA200806756B (en) | 2009-11-25 |
| WO2007093520A1 (en) | 2007-08-23 |
| TW200801010A (en) | 2008-01-01 |
| NO20083585L (no) | 2008-10-28 |
| AU2007216543A1 (en) | 2007-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR059571A1 (es) | Derivados de octahidro-pirrolo[3,4-c]pirrol, composiciones farmaceuticas | |
| PE20060381A1 (es) | Analogos de dipeptidos inhibidores de la hepatitis c | |
| AR047793A1 (es) | Inhibidores de la serina proteasa ns-3 del vhc | |
| AR075050A1 (es) | Dicianopiridinas alquilamino-sustituidas | |
| AR034448A1 (es) | Uso de derivados de nucleosidos, dichos derivados de nucleosidos para dicho uso, composiciones farmaceuticas que los comprenden y uso de dichas composiciones | |
| AR076860A1 (es) | Derivados de 7-aril- 1,2,4-triazolo[4,3-a]piridina moduladores alostericos positivos de receptores mglur2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos neurologicos y siquiatricos. | |
| AR051092A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa | |
| AR086546A1 (es) | Derivados de 7h-purin-8(9h)-ona como inhibidores de jak | |
| AR066669A1 (es) | Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas. | |
| AR043929A1 (es) | Fases cristalinas de un inhibidor del hcv | |
| AR051294A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa | |
| AR040475A1 (es) | Espiropiperidinas o espiropirrolidinas triciclicas | |
| PE20091381A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR043508A1 (es) | 1-amino 1-h-imidazoquinolinas y su uso como inmunomoduladores | |
| PE20050013A1 (es) | Composiciones farmaceuticas como inhibidores de la proteasa del virus de la hepatitis c | |
| AR067542A1 (es) | Compuestos macrociclicos de indol utiles para el tratamiento de hepatitis c | |
| AR044543A1 (es) | Derivados de pirazolo-quinazolina, un procedimiento para su preparacion y su uso como inhibidor de quinasa | |
| AR063240A1 (es) | Derivados de n-aril pirazol,composiciones farmaceuticas que los contienen y usos para el tratamiento de la diabetes tipo2,y enfermedades relacionadas. | |
| AR065772A1 (es) | Compuestos de indolobenzazepina para el tratamiento de la hepatitis c. composiciones farmaceuticas. | |
| AR044011A1 (es) | Antagonistas de mchr1 heterociclicos | |
| CO6270320A2 (es) | Derivados de piperidina utiles como antagonistas del receptor orexina | |
| PE20090042A1 (es) | Analogos de ciclopamina | |
| AR045595A1 (es) | Composiciones utiles como inhibidores de proteinas quinasas | |
| AR049708A1 (es) | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
| PE20011166A1 (es) | Piridinas, pirimidinas, purinonas, pirrolopirimidinonas y pirrolopiridinonas como antagonistas del factor liberador de corticotropina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |